Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Surgical results in patients with CNS lymphoma. Comparison of predictive value of intraoperative MRI and intraoperative histological examination for diagnostic biopsy yield.

Brain & spine·2024

Same author

Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy.

American journal of hematology·2023

Same author

Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury.

Journal of nephrology·2020

Same author

Acute elevation of intraocular pressure in patient with hyperlipidemic myeloma.

Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti·2020

Same author

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data.

Neoplasma·2019

Same author

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.

The European journal of health economics : HEPAC : health economics in prevention and care·2019

Search research articles

Related Experiment Video

Updated: May 9, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

[Multiple myeloma].

I Špička¹, M Klánová

¹I. interní klinika 1. lékařské fakulty UK a VFVN Praha. spicka@cesnet.cz

Vnitrni Lekarstvi

|August 6, 2013

Summary

Targeting drugs like bortezomib and lenalidomide have transformed multiple myeloma treatment, shifting it from a fatal diagnosis to a manageable condition. Ongoing research focuses on maintenance therapy, drug combinations, and next-generation agents.

Area of Science:

Hematology
Oncology
Pharmacology

Background:

Multiple myeloma is a prevalent hematological malignancy with a historically poor prognosis.
Early treatment advances included high-dose therapy with hematopoietic cell support.
The advent of novel targeted therapies marked a significant turning point in patient outcomes.

Purpose of the Study:

To review the impact of novel targeted drugs on multiple myeloma treatment.
To highlight the evolution of multiple myeloma from a fatal disease to a manageable malignancy.
To outline current research directions for improving treatment efficacy.

Main Methods:

Review of therapeutic advancements in multiple myeloma.
Analysis of the impact of targeted agents (thalidomide, bortezomib, lenalidomide).

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: May 9, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Identification of ongoing research strategies for enhanced treatment.

Main Results:

Bortezomib and lenalidomide have dramatically improved multiple myeloma prognosis.
These drugs have converted the disease into a long-term controllable condition.
Some patients may now achieve a curable state.

Conclusions:

Targeted therapies have revolutionized multiple myeloma management.
Future research focuses on maintenance therapy, drug combinations, and next-generation agents.
Multiple myeloma is increasingly viewed as a treatable, chronic malignancy.